全文获取类型
收费全文 | 12418篇 |
免费 | 1161篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 96篇 |
儿科学 | 470篇 |
妇产科学 | 322篇 |
基础医学 | 1577篇 |
口腔科学 | 355篇 |
临床医学 | 1409篇 |
内科学 | 2288篇 |
皮肤病学 | 392篇 |
神经病学 | 1023篇 |
特种医学 | 615篇 |
外科学 | 1798篇 |
综合类 | 307篇 |
一般理论 | 12篇 |
预防医学 | 1327篇 |
眼科学 | 196篇 |
药学 | 852篇 |
中国医学 | 11篇 |
肿瘤学 | 557篇 |
出版年
2021年 | 204篇 |
2020年 | 110篇 |
2019年 | 157篇 |
2018年 | 207篇 |
2017年 | 145篇 |
2016年 | 162篇 |
2015年 | 133篇 |
2014年 | 242篇 |
2013年 | 353篇 |
2012年 | 533篇 |
2011年 | 527篇 |
2010年 | 310篇 |
2009年 | 284篇 |
2008年 | 501篇 |
2007年 | 551篇 |
2006年 | 522篇 |
2005年 | 447篇 |
2004年 | 457篇 |
2003年 | 475篇 |
2002年 | 472篇 |
2001年 | 372篇 |
2000年 | 449篇 |
1999年 | 377篇 |
1998年 | 185篇 |
1997年 | 180篇 |
1996年 | 138篇 |
1995年 | 122篇 |
1994年 | 138篇 |
1993年 | 149篇 |
1992年 | 288篇 |
1991年 | 297篇 |
1990年 | 283篇 |
1989年 | 349篇 |
1988年 | 256篇 |
1987年 | 271篇 |
1986年 | 246篇 |
1985年 | 274篇 |
1984年 | 179篇 |
1983年 | 143篇 |
1982年 | 125篇 |
1981年 | 144篇 |
1980年 | 98篇 |
1979年 | 170篇 |
1978年 | 135篇 |
1977年 | 124篇 |
1976年 | 102篇 |
1975年 | 104篇 |
1974年 | 94篇 |
1973年 | 112篇 |
1972年 | 98篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
M P Rogers K Bloomingdale B J Murawski N A Soter P Reich K F Austen 《Psychosomatic medicine》1986,48(6):437-447
Systemic mastocytosis is a disease characterized by an excessive accumulation of mast cells, and associated with skin lesions, flushing, diarrhea, tachycardia, and psychiatric manifestations. In order to define more clearly the psychiatric manifestations, ten patients with this disorder underwent unstructured psychiatric interviews and a battery of psychologic testing. Both revealed a pattern of cognitive and affective changes in the majority of these patients, best categorized as an atypical or mixed organic brain syndrome. The cognitive changes consisted of diminished attention and memory, and the affective changes of anger, irritability, and, to a lesser extent, depression. These manifestations fluctuated with the level of disease activity, and appeared in some cases to respond to histamine antagonists and disodium cromoglycate, medications used to control the excessive mast cell activity. It is important for psychiatrists to be aware that mental status changes can represent psychiatric manifestations of mastocytosis, a readily treatable medical disorder. 相似文献
992.
Long term outcome of twin-twin transfusion syndrome 总被引:4,自引:0,他引:4
Cincotta RB Gray PH Phythian G Rogers YM Chan FY 《Archives of disease in childhood. Fetal and neonatal edition》2000,83(3):F171-F176
AIMS: To compare the perinatal mortality and morbidity of infants with twin-twin transfusion syndrome (TTTS) with those of gestation matched twin controls and to assess the neurodevelopmental outcome of surviving twins with TTTS. METHODS: A cohort of 17 consecutive pregnancies with TTTS was enrolled over three years together with gestation matched twin pregnancies unaffected by TTTS. Serial amnioreduction for the TTTS pregnancies was performed as appropriate. Perinatal death and neonatal morbidities were recorded for both the TTTS cohort and controls. The TTTS survivors had neurodevelopmental follow up to at least 2 years of age. RESULTS: In 12 of the pregnancies, serial amniocenteses were performed, but, in five, the infants were born before intervention. The mean gestational age at delivery was 29.1 weeks (range 23-36). There were five intrauterine deaths in the TTTS cohort and six neonatal deaths (survival 68%). In the control group, there was one intrauterine death and five neonatal deaths (survival 82%). Infants in the TTTS group had a greater requirement for inotropes (p = 0.04) and a higher incidence of renal failure (p = 0.005). Periventricular leucomalacia and cerebral atrophy were seen in 17% of the TTTS group, but none of the controls (p = 0.03). The 23 surviving TTTS infants were all followed up, with 22% having significant neurological morbidity: cerebral palsy and global developmental delay. CONCLUSIONS: Twins with TTTS have high perinatal mortality and neonatal morbidity, and long term neurodevelopmental morbidity in survivors is high. Further investigation into the pathogenesis and management of TTTS is required. 相似文献
993.
Wilens TE Newcorn JH Kratochvil CJ Gao H Thomason CK Rogers AK Feldman PD Levine LR 《The Journal of pediatrics》2006,149(1):112-119
OBJECTIVE: To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years. STUDY DESIGN: Data from 13 atomoxetine studies (6 double-blind, 7 open-label) were pooled for subjects age 12 to 18 with ADHD as defined by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders IV. RESULTS: Of the 601 atomoxetine-treated subjects in this meta-analysis, 537 (89.4%) completed 3 months of acute treatment. A total of 259 subjects (48.4%) are continuing atomoxetine treatment; 219 of these subjects have completed at least 2 years of treatment. The mean dose of atomoxetine at endpoint was 1.41 mg/kg/day. Mean ADHD Rating Scale IV, parent version, investigator-administered and -scored total scores showed significant improvement (P < .001) over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period, 99 (16.5%) subjects discontinued treatment due to lack of effectiveness, and 31 (5.2%) subjects discontinued treatment due to adverse events. No clinically significant abnormalities in height, weight, blood pressure, pulse, mean laboratory values, or electrocardiography parameters were found. CONCLUSIONS: Two-year data from this ongoing study indicate that atomoxetine maintains efficacy among adolescents with ADHD, with no evidence of drug tolerance and no new or unexpected safety concerns. 相似文献
994.
McGlothan KR Wyatt RJ Ault BH Hastings MC Rogers T DiSessa T Jones DP 《Pediatric transplantation》2006,10(5):558-564
Hypertension is common in children with end-stage renal disease who have undergone renal transplantation. We performed ambulatory blood pressure monitoring (ABPM) in renal allograft recipients who were on stable maintenance immunosuppressive medications and were more than six months post-transplant. Echocardiographic measurement of left ventricular mass index (LVMI) was obtained at the time of ABPM. Twenty-nine children with a mean age of 14.8 yr (8-18 yr) were evaluated 4.3 yr (0.6-12.8 yr) after deceased donor (n = 13) or living donor (n = 16) transplantation. BP levels were higher during sleep compared with when awake using the 95th percentile to standardize mean BP for each period: mean BP was expressed as a standard deviation score (SDS) for each time period, awake vs. sleep: systolic (s) BP SDS were 0.43 +/- 1.3 vs. 1.29 +/- 1.2 (p < 0.001) and diastolic (d) BP SDS were 0.04 +/- 1.3 vs. 1.34 +/- 1.2 (p < 0.001). Significant differences between awake and sleep BP were also confirmed using the mean BP for each period expressed as a BPI. Hypertension (HTN) during sleep was more common than awake HTN. Based upon BPI, 21% had sHTN when awake compared with 48% during sleep and 7% had dHTN when awake compared with 41% during sleep (p < 0.05). Based upon mean BP load, 38% had sHTN when awake compared with 55% during sleep and 21% demonstrated dHTN when awake compared with 52% during sleep (p < 0.05). Left ventricular mass (LVM) was abnormally increased in six of 17 children (35%); LVM was not correlated with BP. Children prescribed angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (ACEi/ARB) had significantly lower systolic BP compared with those on calcium channel blocking agents (CCB). Mean sSDS was -0.11 +/- 1.1 in those children on ACEi/ARB compared with 1.6 +/- 1.2 in those on CCB (p = 0.02): sSDS during sleep was significantly lower in the ACEi/ARB group compared with CCB (0.70 +/- 1.1 vs. 2.0 +/- 1.1, p = 0.04). Isolated nocturnal HTN is more common than daytime HTN among clinically stable pediatric renal allograft recipients. Detection and treatment of nocturnal HTN in pediatric allograft recipients could potentially affect graft survival. 相似文献
995.
996.
Ashish Anand Frederick Balduini Ken Rogers 《European journal of orthopaedic surgery & traumatology : orthopedie traumatologie》2010,20(8):645-649
Intra-articular hyaluronic acid injections is an accepted therapeutic alternative in the symptomatic management of knee osteoarthritis; however there are hardly any studies documenting possible benefit of hyaluronan in delaying the need for TKR. It was this intent our study was conducted. This was a retrospective chart analysis of 130 patients (75 females and 55 males) with varying degree of knee osteoarthritis treated over a 5-year period. The average age was 59.4 (range 15–92). Fifty-three patients had left knee involvement, right knee in 45 patients with 32 with bilateral involvement. Of the patients, 85% had advanced arthritis (grade ¾). All 130 patients had received hyaluronic acid injections. The total number of courses per knee was 1.604. In patients who had more than one course, the minimum interval between courses was 6 months with the longest interval being 36 months. Three patients (2.3%) developed toxic synovitis. Seventeen patients had a poor response at 6 months. Forty-five patients were advised surgery, but only 29 patients underwent surgery. All patients who underwent surgery had Grade 3/4 changes at the initial presentation. Of 109 patients, 65 (58.7%) patients with advanced arthritis did not undergo surgery and were doing well at final follow-up. Thus, hyaluronic acid injections can delay the need for total knee replacement. 相似文献
997.
998.
Coyne KS Margolis MK Brewster-Jordan J Sutherland SE Bavendam T Rogers RG 《The journal of sexual medicine》2007,4(1):124-136
IntroductionTo assess sexual health, relevant, valid, and reliable questionnaires need to be used.AimTo assess the relevance and content validity of three sexual health questionnaires in women with overactive bladder (OAB) and urinary incontinence.Main Outcome MeasuresSexual Quality of Life Questionnaire––Female (SQoL‐F), Sexual Function Questionnaire (SFQ), and Pelvic Organ Prolapse–Incontinence Sexual Function Questionnaire (PISQ).MethodsWomen with OAB and urinary incontinence were recruited from five urology clinics in the United States; those who were interested in participating were mailed questionnaire packets with instructions. Each questionnaire item was followed by three questions regarding the understandability, relevance, and impact of bladder condition when responding to the question. Patients returned the completed questionnaires by mail; clinical information was obtained from chart review.ResultsA total of 129 patients (74% response) returned the questionnaires. The mean age was 56 years; 78% were white; 64% were married. In this sample, 64% had urge incontinence; 32% had mixed incontinence; and 4% had stress incontinence. Participants experienced bladder symptoms for a mean of 12.2 years with the following treatments: surgery (43%), bladder training (26%), exercise/biofeedback (42%), and medications (67%). SQoL‐F items were understood by more than 97% of the respondents, more than 89% for SFQ, and more than 82% for PISQ. There were two SQoL‐F items, one SFQ item, and 11 PISQ items that less than 60% of the respondents deemed relevant to their bladder condition. Correlations among questionnaire items and relevance to bladder condition ranged from 0.04 to 0.64 for the SQoL‐F, 0.04 to 0.47 for the SFQ, and 0.01 to 0.58 for the PISQ.ConclusionWomen with OAB found the majority of items on all three questionnaires to be relevant to their bladder condition. Of these questionnaires, the SQoL‐F had the highest understandability, fewest questions considered irrelevant, and correlated well with OAB symptoms. Coyne KS, Margolis MK, Brewster‐Jordan J, Sutherland SE, Bavendam T, and Rogers RG. Evaluating the impact of overactive bladder on sexual health in women: What is relevant? J Sex Med 2007;4:124–136. 相似文献
999.
Bruce W. Thompson PhD Scott T. Miller MD Zora R. Rogers MD Renee C. Rees PhD Russell E. Ware MD PhD Myron A. Waclawiw PhD Rathi V. Iyer MD James F. Casella MD Lori Luchtman‐Jones MD Sohail Rana MD Courtney D. Thornburg MD Ram V. Kalpatthi MD Julio C. Barredo MD R. Clark Brown MD PhD Sharada Sarnaik MD Thomas H. Howard MD Lori Luck MD Winfred C. Wang MD 《Pediatric blood & cancer》2010,54(2):250-255
Evidence of the laboratory benefits of hydroxyurea and its clinical efficacy in reducing acute vaso‐occlusive events in adults and children with sickle cell anemia has accumulated for more than 15 years. A definitive clinical trial showing that hydroxyurea can also prevent organ damage might support widespread use of the drug at an early age. BABY HUG is a randomized, double‐blind placebo‐controlled trial to test whether treating young children ages 9–17 months at entry with a liquid preparation of hydroxyurea (20 mg/kg/day for 2 years) can decrease organ damage in the kidneys and spleen by at least 50%. Creation of BABY HUG entailed unique challenges and opportunities. Although protection of brain function might be considered a more compelling endpoint, preservation of spleen and renal function has clinical relevance, and significant treatment effects might be discernable within the mandated sample size of 200. Concerns about unanticipated severe toxicity and burdensome testing and monitoring requirements were addressed in part by an internal Feasibility and Safety Pilot Study, the successful completion of which was required prior to enrolling a larger number of children on the protocol. Concerns over recruitment of potentially vulnerable subjects were allayed by inclusion of a research subject advocate, or ombudsman. Finally, maintenance of blinding of research personnel was aided by inclusion of an unblinded primary endpoint person, charged with transmitting endpoint data and monitoring blood work locally for toxicity (ClinicalTrials.gov number, NCT00006400). Pediatr Blood Cancer 2010;54:250–255. © 2009 Wiley‐Liss, Inc. 相似文献